Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL).

Sorry, there's nothing here.

Cite this paper

@article{Tan2016HistoneD, title={Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL).}, author={Daryl Chen Lung Tan and Colin Phipps Diong and Yvonne S M Loh and Y. T. Goh}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2016}, volume={27 9}, pages={1811-2} }